Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

about

Discovery and characterization of olokizumab Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Novel treatment options for ulcerative colitis.

P2860

Q27682535-DE390C7D-3F7B-456F-B6F3-896AF146A0A6 Q37200907-F37D3F0D-EFFC-4971-841D-8A0E3BEC0BC1 Q41949151-54054627-D88E-4DFE-A631-E197FD22ADD5

P2860

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

Item

http://www.wikidata.org/entity/Q38029235

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

@en

type

Item

label

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

@en

prefLabel

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

@en

P1476

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases

@en

P2093

D A Katzka

http://www.w3.org/2001/XMLSchema#string

M Camilleri

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance

Anti-interleukin-12 antibody for active Crohn's disease

Prevalence of eosinophilic esophagitis in adults with food bolus obstruction of the esophagus

Efficacy of Cetuximab in the Treatment of Menetrier's Disease

Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.

Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51.

Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.

Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects.

Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.

P304

306-320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.77

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Edward V Loftus

P577

2012-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230565000

http://www.w3.org/2001/XMLSchema#string

P698

22828717

http://www.w3.org/2001/XMLSchema#string

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

about

P2860

P2860

Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698